CN103494201B - L-抗坏血酸棕榈酸酯配伍的骨关节疾病保健品 - Google Patents
L-抗坏血酸棕榈酸酯配伍的骨关节疾病保健品 Download PDFInfo
- Publication number
- CN103494201B CN103494201B CN201310489557.1A CN201310489557A CN103494201B CN 103494201 B CN103494201 B CN 103494201B CN 201310489557 A CN201310489557 A CN 201310489557A CN 103494201 B CN103494201 B CN 103494201B
- Authority
- CN
- China
- Prior art keywords
- vitamin
- parts
- calcium
- bone
- ascorbyl palmitate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000010099 disease Diseases 0.000 title abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 44
- 239000011575 calcium Substances 0.000 claims abstract description 43
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 43
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 36
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 16
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 16
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 13
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 10
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 8
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 8
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 8
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 8
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 8
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 8
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940067606 lecithin Drugs 0.000 claims abstract description 8
- 235000010445 lecithin Nutrition 0.000 claims abstract description 8
- 239000000787 lecithin Substances 0.000 claims abstract description 8
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960002477 riboflavin Drugs 0.000 claims abstract description 8
- 229960003495 thiamine Drugs 0.000 claims abstract description 8
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 8
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 8
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 8
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 8
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 8
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 8
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 8
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 8
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 8
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 8
- 239000011709 vitamin E Substances 0.000 claims abstract description 8
- 229940046009 vitamin E Drugs 0.000 claims abstract description 8
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 8
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims abstract description 7
- 239000011790 ferrous sulphate Substances 0.000 claims abstract description 7
- 235000003891 ferrous sulphate Nutrition 0.000 claims abstract description 7
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims abstract description 7
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims abstract description 7
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 7
- 229940050168 zinc lactate Drugs 0.000 claims abstract description 7
- 239000011576 zinc lactate Substances 0.000 claims abstract description 7
- 235000000193 zinc lactate Nutrition 0.000 claims abstract description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 6
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 6
- 239000011719 vitamin A Substances 0.000 claims abstract description 6
- 229940045997 vitamin a Drugs 0.000 claims abstract description 6
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 19
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 19
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 19
- 208000020084 Bone disease Diseases 0.000 claims description 13
- 208000012659 Joint disease Diseases 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- -1 2.5 parts Chemical compound 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 12
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 239000003053 toxin Substances 0.000 abstract description 2
- 231100000765 toxin Toxicity 0.000 abstract description 2
- 235000015097 nutrients Nutrition 0.000 abstract 2
- 238000007599 discharging Methods 0.000 abstract 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 abstract 1
- 102000008186 Collagen Human genes 0.000 description 18
- 108010035532 Collagen Proteins 0.000 description 18
- 229920001436 collagen Polymers 0.000 description 17
- 239000000047 product Substances 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 108010048734 sclerotin Proteins 0.000 description 6
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000037182 bone density Effects 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- CPGKMLVTFNUAHL-UHFFFAOYSA-N [Ca].[Ca] Chemical compound [Ca].[Ca] CPGKMLVTFNUAHL-UHFFFAOYSA-N 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- RHAXKFFKGZJUOE-UHFFFAOYSA-N 7-acetyl-6-ethyl-3,5,8-trihydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid Chemical compound O=C1C2=CC(O)=C(C(O)=O)C(C(O)=O)=C2C(=O)C2=C1C(O)=C(CC)C(C(C)=O)=C2O RHAXKFFKGZJUOE-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000002240 Tennis Elbow Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 208000022458 calcium metabolism disease Diseases 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 201000010603 frozen shoulder Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010220 ion permeability Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种L-抗坏血酸棕榈酸酯配伍的骨关节疾病保健品，由以下原料按重量份数制成：L-抗坏血酸棕榈酸酯38-45份、维生素A1.0-1.1份、维生素B11.2-1.3份、维生素B21.2-1.3份、维生素B60.1-0.2份、维生素B120.001-0.002份、维生素E2.2-2.3份、乳酸锌1.2-1.4份、硫酸亚铁2.0-2.2份、螯合钙100-120份、氧化镁1.0-1.3份、卵磷脂2.3-2.7份。本发明属脂溶性物质，充分考虑现代人体所需养料，合理配伍养料，具备排除骨关节毒素、有助促进自身骨胶原生成和钙吸收。
Description
技术领域
本发明涉及一种骨关节疾病的保健品，具体地说涉及一种由L-抗坏血酸棕榈酸酯配伍的骨关节疾病保健品。
背景技术
骨关节疾病是一类常见病，最新的骨科学研究惊人发现：关节疼痛、肿胀、僵硬、无力感、嘎嘎作响、软骨磨损等疾病的根源是骨胶原受到免疫系统的错误攻击，绝非缺钙造成。骨胶原是存在于人体和动物体内的胶原蛋白的一种，是人体关节软骨，骺软骨和骨小梁的主要成份，骨骼有机物中有70％～86％是骨胶原。骨胶原也是组成人体肌肉、皮肤的重要成分，对于保持骨骼的韧性、人体运动的协调性及皮肤的弹性有很大帮助。
人体自身对一种名为爱泼斯坦(EpsteinBarr，简称EB)的病毒有遗传性的先天性过敏，而这种病毒的氨基酸和人体骨胶原内的氨基酸非常相似，所以当人体免疫系统产生抗体攻击爱泼斯坦病毒时，也错误地把软骨内的骨胶原当成外来异物加以攻击(也称“免疫交叉反应”)，因而使软骨受损，润滑度变差；软骨表面长出骨刺，肿胀，关节间的空隙变小，活动受阻，疼痛不已，如果缺乏治疗，最终将导致骨头破裂。免疫系统的问题只有从免疫系统入手才能解决。骨胶原经过胃，被小肠淋巴识别后，使免疫系统产生“耐受”认同作用，直达软骨组织，快速修复软骨，消除关节的疼痛、肿胀、僵硬、无力感、有响声、骨质增生、骨刺、五十肩、网球肘等，这个过程叫“口服免疫耐受作用”(OralTolerization)。
预防和治疗骨关节问题单纯的补充钙质是不能完全解决问题的，钙的高吸收率必须辅助较高的钙沉积和较高的利用率才能从根本上解决问题。足够的钙摄入量和相应的胶原纤维是成骨的重要条件，缺一不可，这也是防止骨关节问题的要素之一。骨胶原和钙可充分有效地增加骨密度，增强骨骼的弹性和韧性，从而建立和恢复良好的、正常的骨质，才能有效防止骨关节问题。当人体在年轻时胶原蛋白的合成速率与分解速率相当，并不会产生胶原蛋白缺乏的问题，而自25岁之后，人体合成胶原蛋白速率开始下降，于是胶原蛋白开始产生缺乏的问题。一旦胶原蛋白开始缺乏，可能会产生关节软骨代谢速度慢，导致活动度差，慢慢形成退化性关节炎；骨质开始大量流失。
胶原蛋白的生成主要有两种途径，一是食用含有蛋白质的食物，在消化道内分解成氨基酸，然后被小肠吸收，通过血液运输至各个细胞，然后细胞核内控制胶原蛋白的基因转录成信使RNA，信使RNA利用氨基酸就合成胶原蛋白。大分子胶原蛋白进入人体后需要降解为小分子肽、氨基酸才能被人体吸收，真正有效吸收的成分并不多，而且这些食物多半脂肪含量较高，不适合经常食用。二是胶原蛋白的自我生成。
这几年胶原蛋白的产品繁多种类繁多，市面上内服的、外涂的五花八门，补充的胶原蛋白产品都是从动物身上提取，对肠胃有刺激、分子大、不易吸收、长期使用有排异性、易引发各类皮肤病。
钙在人体内的含量是比较多的，成人体内含钙总量为1200～2000g，约为体重的2％左右。体内的钙以两种形式存在：99％以上的钙与磷一起以羟基磷灰石的形式构成骨盐，存在于骨骼和牙齿中，其余约1％的钙以离子形式存在于软组织、细胞外液和血液中，统称混溶钙池。上述两种钙保持着动态平衡状态。骨中的钙不断从破骨细胞中释放，进入钙池，而钙池中的钙离子则不断沉积于成骨细胞中，形成新骨。
钙在体内的分布既恒定又平衡，这对机体的生命至关重要。人体内的钙有如下生理功能包括：形成肌体的骨骼、牙齿等硬组织成分；细胞内的化学信使，影响神经细胞的传递，凝血机制离不开钙；控制肌凝蛋白、肌动蛋白、ATP 间基本反应所必需的触发剂；影响细胞膜的离子通透性。钙缺乏时，导致体内钙含量、钙平衡、钙浓度梯度发生变化，造成钙代谢紊乱，导致机体产生诸多疾病，常见的如骨质疏松，表现为骨的脆性增加，身高缩短、驼背、腰背痛疼、骨折。
如果饮食中钙摄入量不足，或是肠道对钙的吸收减少，就会引起机体负钙平衡。为了维持正常的血钙水平，机体会通过增加甲状旁腺激素分泌等促进骨质溶解，使骨骼中的钙“迁徙”到血液中，从而导致骨质减少，即骨量丢失。这种钙入不敷出的状态长期延续，骨质就会变得疏松多孔而易于骨折。而市面上的补钙产品主要分有机钙和无机钙，无机钙钙含量较高，但不易溶解，在人体中需要消耗大量胃酸使钙游离出来成离子状态才能被吸收，对胃肠道有一定的刺激作用，有机钙含钙量低于无机钙，往往需要服用多剂量。
发明内容
本发明针对现有技术的不足，提供一种促进骨胶原生成和钙吸收的脂溶性骨关节疾病保健品。
为了实现上述目的，本发明采用的技术方案是：
一种L-抗坏血酸棕榈酸酯配伍的骨关节疾病保健品，由以下原料按重量份数制成：L-抗坏血酸棕榈酸酯 38-45份、维生素A 1.0-1.1份、维生素B1 1.2-1.3份、维生素B2 1.2-1.3份、维生素B6 0.1-0.2份、维生素B12 0.001-0.002份、维生素E 2.2-2.3份、乳酸锌 1.2-1.4份、硫酸亚铁 2.0-2.2份、螯合钙 100-120份、氧化镁 1.0-1.3份、卵磷脂2.3-2.7份。
上述的一种L-抗坏血酸棕榈酸酯配伍的骨关节疾病保健品，由以下原料按重量份数制成：L-抗坏血酸棕榈酸酯 42份、维生素A 1份、维生素B1 1.25份、维生素B2 1.25份、维生素B6 0.15份、维生素B12 0.0015份、维生素E 2.25份、乳酸锌 1.30份、硫酸亚铁 2.2份、螯合钙 110份、氧化镁 1.2份、卵磷脂 2.5份。
本发明利用氨基酸及L-抗坏血酸棕榈酸酯来重建骨质，没有副作用，且可借此提升人类生长激素，有抗老化的作用。人类生长激素可以修复五脏六腑，骨骼（髓）本身属于造血器官，很自然也在修复名单之列，因此利用此基本的原理，利用L-抗坏血酸棕榈酸酯促进骨胶原的生成，找到安全无副作用的对骨关节疾病的治疗方法。
L-抗坏血酸棕榈酸酯是一种脂溶性维生素C衍生物，它能够隔离氧对水溶性维生素C造成的不稳定因素，L-抗坏血酸棕榈酸酯能够快速通过消化道粘膜的细胞间隙直接进入人体细胞，可溶于血液、细胞膜及脂质，由于赖氨酸、脯氨酸是小分子物质，因此，赖氨酸和脯氨酸，加上L-抗坏血酸棕榈酸酯合成人体自身胶原蛋白，同时为细胞提供足够的活性原材料，提高酶活性，激活细胞的潜能，启动身体自我修复机制，使很多临床上看不到希望的慢性问题、免疫问题得到很好的再生修复以至康复。
骨代谢与氨基酸同样有着密切的关系，赖氨酸是协助肠内钙质的吸收与骨质胶原蛋白形成的要素，又可抑制摄入的钙质从尿液中流失，可强化精氨酸的效果。
维生素A、维生素B1、维生素B2、维生素B6、维生素B12和维生素E的加入起到抗氧化的作用，不仅减少自由基对胶原蛋白的破坏，还能有效促进体内胶原蛋白的有效合成。维生素A可以间接影响钙功能的发挥，因为维生素A能促进蛋白质的合成和骨细胞的分化、能促进粘多糖合成，影响骨组织的更新发育。
补充微量元素的摄入。当人体内镁、锌摄入不足时，破骨细胞的活性便会增强，而成骨细胞的活性却受到抑制，成长速度减慢，造成成骨障碍。临床研究表明，镁、锌等摄入不足，也会对骨量的维持产生不良的影响。本发明采用的钙为螯合钙在血液中形成一种流动缓冲的“流动钙库”在需要钙的地方，能缓慢释放钙离子，不会因为浓度过高引起高钙血病。微量元素铁是红细胞血红蛋白的重要成分，血红蛋白把氧带到组织细胞中，如缺铁就不能合成血红蛋白，氧就无法输送，组织细胞就不能进行正常代谢，加入适量铁，提高本发明的生物利用度。
卵磷脂有增强骨细胞机能的功能对骨细胞生长有一定的作用，因此磷脂对骨折后骨骼恢复健康也是十分有益的。
本发明属脂溶性物质，充分考虑现代人体所需养料，以及基因表达的环境变化，合理配伍养料。有效改善肠胃，同时具备以下功效：
（1）在人体内停留36-48小时，排除骨关节毒素；
（2）有助促进自身骨胶原生成；
（3）生物利用率是普通水溶性补钙产品的10倍；
（4）可祛肿、消炎，促进伤口愈合。
具体实施方式
实施例1 一种L-抗坏血酸棕榈酸酯配伍的骨关节疾病保健品
原料组分：L-抗坏血酸棕榈酸酯40毫克、维生素A 1毫克、维生素B1 1.20毫克、维生素B2 1.20毫克、维生素B6 0.10毫克、维生素B12 1.0微克、维生素E 2.25毫克、乳酸锌 1.20毫克、硫酸亚铁 2.0毫克、螯合钙 100毫克、氧化镁 1.0毫克、卵磷脂2.3毫克。
制备方法：将上述各原料按比例混合均匀，干燥后分装胶囊中，即可得到胶囊剂，每粒胶囊剂的原料组成如上。
实施例2一种L-抗坏血酸棕榈酸酯配伍的骨关节疾病保健品
原料组分：L-抗坏血酸棕榈酸酯 42毫克、维生素A 1毫克、维生素B1 1.25毫克、维生素B2 1.25毫克、维生素B6 0.15毫克、维生素B12 1.5微克、维生素E 2.25毫克、乳酸锌 1.30毫克、硫酸亚铁 2.2毫克、螯合钙 110毫克、氧化镁 1.2毫克、卵磷脂2.5毫克。
制备方法：将上述各原料粉混合均匀，进行造粒、干燥后分装，即可得到颗粒剂，每粒颗粒剂的原料组成如上。
实例3 效果实施例
以实例2的颗粒，随机选取男50人，女50人，年龄65~75岁，用于改善骨关节疼痛、关节僵硬及腰膝酸软等症状，每人每日服用4粒，服用3个月，总有效率92%，具体情况如下：
1）痊愈：经治疗后恢复45人。
2）显效：经治疗后关节疼痛明显减轻，关节僵硬明显减轻，腰膝酸软明显减少，骨密度指标明显恢复，免疫力增强15人。
3）好转：经治疗后关节疼痛稍微减轻，关节僵硬稍微减轻，腰膝酸软稍微减少，骨密度指标稍微恢复，免疫力稍微增强32人。
4）无效：经治疗后关节疼痛没有减轻，关节僵硬没有减轻，腰膝酸软没有减少，骨密度指标没有恢复，免疫力没有增强8人。
Claims (2)
1.一种L-抗坏血酸棕榈酸酯配伍的骨关节疾病保健品，其特征在于：由以下原料按重量份数制成：L-抗坏血酸棕榈酸酯 38-45份、维生素A 1.0-1.1份、维生素B1 1.2-1.3份、维生素B2 1.2-1.3份、维生素B6 0.1-0.2份、维生素B12 0.001-0.002份、维生素E 2.2-2.3份、乳酸锌 1.2-1.4份、硫酸亚铁 2.0-2.2份、螯合钙 100-120份、氧化镁 1.0-1.3份、卵磷脂2.3-2.7份。
2.如权利要求1所述的一种L-抗坏血酸棕榈酸酯配伍的骨关节疾病保健品，其特征在于：由以下原料按重量份数制成：L-抗坏血酸棕榈酸酯 42份、维生素A 1份、维生素B1 1.25份、维生素B2 1.25份、维生素B6 0.15份、维生素B12 0.0015份、维生素E 2.25份、乳酸锌 1.30份、硫酸亚铁 2.2份、螯合钙 110份、氧化镁 1.2份、卵磷脂 2.5份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310489557.1A CN103494201B (zh) | 2013-10-18 | 2013-10-18 | L-抗坏血酸棕榈酸酯配伍的骨关节疾病保健品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310489557.1A CN103494201B (zh) | 2013-10-18 | 2013-10-18 | L-抗坏血酸棕榈酸酯配伍的骨关节疾病保健品 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103494201A CN103494201A (zh) | 2014-01-08 |
| CN103494201B true CN103494201B (zh) | 2015-03-11 |
Family
ID=49859540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310489557.1A Active CN103494201B (zh) | 2013-10-18 | 2013-10-18 | L-抗坏血酸棕榈酸酯配伍的骨关节疾病保健品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103494201B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113100251B (zh) * | 2021-04-25 | 2025-09-02 | 渭南东旺农华生物科技有限公司 | 一种包含卵磷脂的农用组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1329077C (zh) * | 2002-11-18 | 2007-08-01 | 上海医药工业研究院 | 增强骨质的蛋白制剂及制备方法 |
| DE20310493U1 (de) * | 2003-07-08 | 2003-10-23 | Orthomol pharmazeutische Vertriebs GmbH, 40764 Langenfeld | Mikronährstoffkombinationsprodukt, geeignet zur nutritiven Ergänzung bei entzündlich-rheumatischen Erkrankungen |
| CN101720928A (zh) * | 2008-10-27 | 2010-06-09 | 柯宏 | 一种防治骨骼及关节退行性疾病的组合物 |
| CN103083621A (zh) * | 2013-02-07 | 2013-05-08 | 涂雪莲 | 一种治疗骨关节炎的药物组合物 |
-
2013
- 2013-10-18 CN CN201310489557.1A patent/CN103494201B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103494201A (zh) | 2014-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101248882B (zh) | 一种具有促进骨骼和骨关节健康的营养食品 | |
| DK2730286T3 (en) | Composition for maintaining bone health and for treating osteoarthritis and osteoarthrosis of the joints | |
| CN103783532B (zh) | 一种抗老年性肌肉衰减的复合蛋白质粉及其制备方法 | |
| CN106135890A (zh) | 一种有助于骨关节健康的营养组合物 | |
| JP2019516412A (ja) | 低分子コラーゲンペプチドおよびこれを用いた食品組成物の製造方法 | |
| US20080069862A1 (en) | Joint preserving nutritional vitamin, mineral and herbal pet supplement | |
| CN101695382A (zh) | 兼具改善骨骼及关节功能的补钙制剂 | |
| CN108703249A (zh) | 一种胶原蛋白产品及其制备方法 | |
| CN102423487A (zh) | 一种骨关节保健组合物及其应用 | |
| CN107348522A (zh) | 一种改善老年人运动系统功能的营养组合物及其制备方法 | |
| CN108576816A (zh) | 一种增加骨密度的组合物 | |
| KR20140075844A (ko) | 알긴산을 포함하는 골관절염 예방 또는 치료용 조성물 | |
| CN103656626B (zh) | 一种中老年治骨养骨复方络合钙制剂及其制备方法 | |
| CN101455396A (zh) | 一种促进骨和骨关节健康的营养保健食品 | |
| CN103494201B (zh) | L-抗坏血酸棕榈酸酯配伍的骨关节疾病保健品 | |
| MXPA05004994A (es) | Composicion para el tratamiento de enfermedades gastrointestinales. | |
| CN101416734A (zh) | 一种改善骨骼及关节功能的保健品及其制备方法 | |
| CN101268836B (zh) | 一种营养高钙冲剂及其生产制作工艺 | |
| CN107929721A (zh) | 一种具有促进青少年骨骼生长和增高功效的配方产品 | |
| CN109464651A (zh) | 一种软骨代谢异常疾病改善用健康食品及药品组合物 | |
| CN108815505A (zh) | 提高中老年人骨密度和骨关节功能避免腰腿抽筋的组合物 | |
| CN105267949A (zh) | 退行性关节炎暨骨质疏松症的药物组方及其片剂制备方法 | |
| CN103211836A (zh) | 一种治疗骨质疏松的组合物 | |
| JP2011223965A (ja) | コラーゲンを含む食品化合物 | |
| CN104888192A (zh) | 一种增加骨密度的海参氨糖制剂及其生产方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190201 Address after: 116620 19-3-2-2 ShuangD4 Street, Dalian Economic and Technological Development Zone, Liaoning Province Patentee after: One bio engineering technology (Dalian) Co., Ltd. Address before: 116620 Unit 19-3, ShuangD Port, ShuangD Fourth Street, Jinzhou New District, Dalian City, Liaoning Province Patentee before: Dalian 5 land 78 bioengineering Co., Ltds |